Home > Business Cases > Understanding hepatotoxicity of new compounds
Understanding hepatotoxicity of new compounds
Situation
A company is developing a new compound for Alzheimer Disease, currently in Phase III. Clinical data shows some risk of hepatotoxicity. Client wants to understand why this is happening, and if patients at risk can be discriminated. Client has preclinical data and microarray data in humans and animals (rats and dogs).
Anaxomics Strategy
Anaxomics created the biological network around known targets of compound, known proteins involved in AD and known proteins and pathways in hepatotox. The resulting map included 1000+ nodes.
Also, we created different maps for different species, and for different types of patients (those with hepatotox vs those without hepatotox).
Solution and Practical Use
We developed a model that explained the mechanistic relationship between drug's
targets and hepatoxicity only in certain conditions.
Biomarkers for hepatotox were hypothesized and are currently being tested in clinical setting. If hepatotox is confirmed, Client wants to develop an accompanying diagnostic biomarker test.
Please, contact us here to request more information.
